Pembrolizumab
UCDCC#289
Phase 2 mab terminated
Quick answer
Pembrolizumab for Advanced Urothelial Carcinoma is a Phase 2 program (mab) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Karyopharm Therapeutics
- Indication
- Advanced Urothelial Carcinoma
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated